AtriCure, Inc.

ATRC

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001323885

A

strongest fifth of 305 graded peers in healthcare

rank 19 of 305; percentile 5.9; sampling error 2.8 points; lower is stronger


A B C D E

A, the bull




Scoreboard	
Profitability	A/B percentile 18.4
Solvency	B percentile 35.7
Growth and financing	B percentile 36.9
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $654.2M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress
Inputs computable	8 of 13
Graded from	filings received through Feb 19, 2026 272 days before the rescan; latest periodic filing 10-Q received Nov 4, 2026
Last close	$55.05 2026-11-17; market equity $2.8B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 19, 2026

We are a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib or AF), left atrial appendage (LAA) management and post-operative pain management. Afib is an irregular heartbeat, or arrhythmia, which affects over 59 million people worldwide and is a growing epidemic. It is the most common cardiac arrhythmia encountered in clinical practice and results in high utilization of healthcare services and significant cost burden. Patients often progress from being in Afib intermittently (paroxysmal) to being in Afib continuously (non-paroxysmal).

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 18.4						
Gross profitability	61.3%	32.8%		15.7	346	2025-12-31
Return on invested capital	not computable	9.6%				


pretax income must exceed the validity floor and imply a 0%-100% tax rate

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(10.9%)	(6.7%)	38.3	756	2025-12-31
Gross margin stability, five years	0.3 pts	2.8 pts	1.3	237	2025-12-31
Solvency, sleeve percentile 35.7					
Altman Z double-prime	3.44	0.31	24.4	705	2025-12-31
Net debt to EBITDA	not computable	1.82x			
EBITDA must exceed $100,000					
Interest coverage	not computable	(3.61x)			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Current ratio	3.96x	2.68x	47.1	781	2025-12-31
Growth and financing, sleeve percentile 36.9					
Revenue growth, three-year compound	17.4%	9.6%	35.6	400	2025-12-31
Free cash flow growth, three-year compound	not computable	11.1%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	33.9%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	3.8%	3.2%	43.8	663	2025-12-31
Net share issuance, one year	1.9%	1.6%	31.4	625	2026-02-12

Among 305 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
14	SBC Medical Group Holdings Inc. (SBC)	4.3	A	fortress balance sheet
15	Biomarin Pharmaceutical Inc. (BMRN)	4.6	A	
16	Exelixis, Inc. (EXEL)	4.9	A	fortress balance sheet
17	Corcept Therapeutics Inc. (CORT)	5.3	A	fortress balance sheet
18	Neurocrine Biosciences Inc. (NBIX)	5.6	A	
19	AtriCure, Inc. (ATRC)	5.9	A	
20	iRhythm Holdings, Inc. (IRTC)	6.2	A	fortress balance sheet
21	Intuitive Surgical Inc. (ISRG)	6.6	A	
22	Gyre Therapeutics, Inc. (GYRE)	6.9	A	fortress balance sheet
23	Vericel Corp. (VCEL)	7.2	A	
24	United Therapeutics Corp. (UTHR)	7.6	A	

What the price implies

at the 2026-11-17 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	62.7%	(1.7%)	84
Distance from 52-week high	(16.0%)	(30.5%)	67
EBIT to enterprise value	(0.4%)	0.5%	46
Free cash flow yield	1.7%	0.5%	58
Book value to price	0.19	0.28	38
Sales to price	0.19	0.36	31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Composite equity issuance, five years	11.1%	13.5%	48
Relative strength against the sector, log excess return	0.32	(0.19)	84
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 7 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$187.0M
Operating cash flow, four quarters	$68.5M
Months of runway	not finite
Days since last periodic filing	14 (10-Q received Nov 4, 2026)
Median daily dollar volume, 63 sessions	$47.2M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$400.8M	2025-12-31	2026-02-19	10-K	26-000007
2	assets	us-gaap:Assets	$654.2M	2025-12-31	2026-02-19	10-K	26-000007
3	operating income	us-gaap:OperatingIncomeLoss	-$42.7M	2022-12-31	2025-02-14	10-K	25-000009
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$46.2M	2022-12-31	2025-02-14	10-K	25-000009
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$268,000	2022-12-31	2025-02-14	10-K	25-000009
6	total debt	us-gaap:LongTermDebt	$60.0M	2022-12-31	2023-02-22	10-K	23-000015
7	book equity	us-gaap:StockholdersEquity	$456.8M	2022-12-31	2026-02-19	10-K	26-000007
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$58.1M	2022-12-31	2024-02-16	10-K	24-000016
9	total debt	us-gaap:LongTermDebt	$60.0M	2021-12-31	2022-02-17	10-K	22-000011
10	book equity	us-gaap:StockholdersEquity	$483.8M	2021-12-31	2025-02-14	10-K	25-000009
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$43.7M	2021-12-31	2023-02-22	10-K	23-000015
12	net income	us-gaap:NetIncomeLoss	-$11.4M	2025-12-31	2026-02-19	10-K	26-000007
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$57.3M	2025-12-31	2026-02-19	10-K	26-000007
14	assets	us-gaap:Assets	$609.3M	2024-12-31	2026-02-19	10-K	26-000007
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$534.5M	2025-12-31	2026-02-19	10-K	26-000007
16	gross profit	us-gaap:GrossProfit	$347.5M	2024-12-31	2026-02-19	10-K	26-000007
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$465.3M	2024-12-31	2026-02-19	10-K	26-000007
18	gross profit	us-gaap:GrossProfit	$300.4M	2023-12-31	2026-02-19	10-K	26-000007
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$399.2M	2023-12-31	2026-02-19	10-K	26-000007
20	gross profit	us-gaap:GrossProfit	$245.9M	2022-12-31	2025-02-14	10-K	25-000009
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$330.4M	2022-12-31	2025-02-14	10-K	25-000009
22	gross profit	us-gaap:GrossProfit	$205.9M	2021-12-31	2024-02-16	10-K	24-000016
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$274.3M	2021-12-31	2024-02-16	10-K	24-000016
24	current assets	us-gaap:AssetsCurrent	$322.5M	2025-12-31	2026-02-19	10-K	26-000007
25	current liabilities	us-gaap:LiabilitiesCurrent	$81.5M	2025-12-31	2026-02-19	10-K	26-000007
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$413.2M	2025-12-31	2026-02-19	10-K	26-000007
27	operating income	us-gaap:OperatingIncomeLoss	-$9.4M	2025-12-31	2026-02-19	10-K	26-000007

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

28	book equity	us-gaap:StockholdersEquity	$491.9M	2025-12-31	2026-02-19	10-K	26-000007
29	liabilities	us-gaap:Liabilities	$162.2M	2025-12-31	2026-02-19	10-K	26-000007
30	depreciation amortization	us-gaap:Depreciation	$8.1M	2022-12-31	2025-02-14	10-K	25-000009
31	operating income	us-gaap:OperatingIncomeLoss	-$26.7M	2023-12-31	2026-02-19	10-K	26-000007
32	interest expense	us-gaap:InterestExpense	$6.9M	2023-12-31	2024-02-16	10-K	24-000016
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$9.1M	2025-12-31	2026-02-19	10-K	26-000007
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$12.2M	2024-12-31	2026-02-19	10-K	26-000007
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$11.5M	2024-12-31	2026-02-19	10-K	26-000007
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$4.5M	2023-12-31	2026-02-19	10-K	26-000007
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$12.0M	2023-12-31	2026-02-19	10-K	26-000007
38	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$22.1M	2022-12-31	2025-02-14	10-K	25-000009
39	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$16.9M	2022-12-31	2025-02-14	10-K	25-000009
40	depreciation amortization	us-gaap:Depreciation	$12.1M	2025-12-31	2026-02-19	10-K	26-000007
41	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$10.2M	2025-12-31	2026-02-19	10-K	26-000007
42	income tax	us-gaap:IncomeTaxExpenseBenefit	$1.3M	2025-12-31	2026-02-19	10-K	26-000007
43	current assets	us-gaap:AssetsCurrent	$267.8M	2024-12-31	2026-02-19	10-K	26-000007
44	current liabilities	us-gaap:LiabilitiesCurrent	$73.4M	2024-12-31	2026-02-19	10-K	26-000007
45	assets	us-gaap:Assets	$613.9M	2023-12-31	2025-02-14	10-K	25-000009
46	assets	us-gaap:Assets	$585.4M	2022-12-31	2024-02-16	10-K	24-000016
47	shares outstanding	dei:EntityCommonStockSharesOutstanding	49,809,901	2026-02-12	2026-02-19	10-K	26-000007
48	shares outstanding	dei:EntityCommonStockSharesOutstanding	48,879,604	2025-02-11	2025-02-14	10-K	25-000009

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.